For the quarter ending 2025-09-30, ABUS made $529,000 in revenue. -$7,684,000 in net income. Net profit margin of -1452.55%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Revenues | 529,000 | 10,739,000 | 1,764,000 | 1,553,000 |
| Research and development | 5,778,000 | 5,498,000 | 8,959,000 | 12,106,500 |
| General and administrative | 3,044,000 | 3,328,000 | 5,832,000 | 5,012,000 |
| Change in fair value of contingent consideration | 268,000 | 260,000 | 299,000 | 656,250 |
| Restructuring costs | 98,000 | 165,000 | 12,373,000 | 31,666.667 |
| Total operating expenses | 9,188,000 | 9,251,000 | 27,463,000 | 18,201,000 |
| Loss from operations | -8,659,000 | 1,488,000 | -25,699,000 | -16,648,000 |
| Interest income | 952,000 | 1,042,000 | 1,197,000 | 1,504,500 |
| Interest expense | 23,000 | 28,000 | 28,000 | 36,000 |
| Foreign exchange (loss) gain | -12,000 | 21,000 | 4,000 | -23,000 |
| Total other income | 917,000 | 1,035,000 | 1,173,000 | 1,444,500 |
| Loss before income taxes | - | - | - | -17,480,000 |
| Income tax expense | - | - | - | 2,276,500 |
| Net loss | -7,742,000 | 2,523,000 | -24,526,000 | -15,203,500 |
| Unrealized gain on available-for-sale securities | 58,000 | -21,000 | -31,000 | 71,500 |
| Comprehensive loss | -7,684,000 | 2,502,000 | -24,557,000 | -15,201,000 |
| Basic (in shares) | 191,778,950 | 191,551,282 | 190,707,085 | -95,714,904.5 |
| Basic (in usd per share) | -0.04 | 0.01 | -0.13 | -0.085 |
| Diluted (in shares) | 191,778,950 | 192,399,733 | 190,707,085 | -95,714,904.5 |
| Diluted (in usd per share) | -0.04 | 0.01 | -0.13 | -0.085 |
Arbutus Biopharma Corp (ABUS)
Arbutus Biopharma Corp (ABUS)